Literature DB >> 12743811

High susceptibility of nullizygous p53 knockout mice to colorectal tumor induction by 1,2-dimethylhydrazine.

Hiroki Sakai1, Tetsuya Tsukamoto, Masami Yamamoto, Norimitsu Shirai, Takeshi Iidaka, Akihiro Hirata, Tokuma Yanai, Toshiaki Masegi, Lawrence A Donehower, Masae Tatematsu.   

Abstract

PURPOSE: The susceptibility of male p53 nullizygote (-/-), heterozygote (+/-), and wild-type (+/+) mice to 1,2-dimethylhydrazine (DMH) induction of colon carcinogenesis was investigated.
METHODS: In a preliminary short-term experiment, male mice of three genotypes were given s.c. of 20 mg/kg DMH once weekly for 5 weeks. In a medium-term experiment, mice were given weekly s.c. of DMH for 15 weeks. In a long-term experiment, male p53 (+/-) and (+/+) mice were given weekly injections of DMH for 15 weeks, and killed at week 30.
RESULTS: In the medium-term experiment, carcinomas were observed in 70% of p53 (-/-) mice, although there were no carcinomas in p53 (+/+) and (+/-) mice. In the long-term experiment, there was no significant difference in incidences of adenomas and carcinomas between p53 (+/+) and (+/-) mice. PCR-single strand conformation polymorphism analysis of exons 5-8 of p53 gene revealed four mutations in one focal atypia, one adenoma, and two carcinomas, out of 56 colonic proliferative lesions in the medium- and long-term experiments.
CONCLUSIONS: These results suggest that p53 might not be a direct target of DMH but complete loss of p53 might elevate susceptibility to DMH-induced colorectal carcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12743811     DOI: 10.1007/s00432-003-0443-9

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  18 in total

1.  p53 knockout mice (-/-) are more susceptible than (+/-) or (+/+) mice to N-methyl-N-nitrosourea stomach carcinogenesis.

Authors:  M Yamamoto; T Tsukamoto; H Sakai; N Shirai; H Ohgaki; C Furihata; L A Donehower; K Yoshida; M Tatematsu
Journal:  Carcinogenesis       Date:  2000-10       Impact factor: 4.944

2.  Cancer. p53, guardian of the genome.

Authors:  D P Lane
Journal:  Nature       Date:  1992-07-02       Impact factor: 49.962

Review 3.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

4.  Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats.

Authors:  S H Erdman; H D Wu; L J Hixson; D J Ahnen; E W Gerner
Journal:  Mol Carcinog       Date:  1997-06       Impact factor: 4.784

5.  Frequent beta-catenin gene mutations and accumulations of the protein in the putative preneoplastic lesions lacking macroscopic aberrant crypt foci appearance, in rat colon carcinogenesis.

Authors:  Y Yamada; N Yoshimi; Y Hirose; K Kawabata; K Matsunaga; M Shimizu; A Hara; H Mori
Journal:  Cancer Res       Date:  2000-07-01       Impact factor: 12.701

Review 6.  p53 mutations in human cancers.

Authors:  M Hollstein; D Sidransky; B Vogelstein; C C Harris
Journal:  Science       Date:  1991-07-05       Impact factor: 47.728

7.  Differential susceptibility of 3 sublines of C57BL/6 mice to the induction of colorectal tumors by 1,2-dimethylhydrazine.

Authors:  B A Diwan; K E Blackman
Journal:  Cancer Lett       Date:  1980-04       Impact factor: 8.679

8.  Reduction of p53 gene dosage does not increase initiation or promotion but enhances malignant progression of chemically induced skin tumors.

Authors:  C J Kemp; L A Donehower; A Bradley; A Balmain
Journal:  Cell       Date:  1993-09-10       Impact factor: 41.582

9.  Primary monoclonal and secondary polyclonal growth of colon neoplastic lesions in C3H/HeN<-->BALB/c chimeric mice treated with 1,2-dimethylhydrazine immunohistochemical detection of C3H strain-specific antigen and simple sequence length polymorphism analysis of DNA.

Authors:  M Tatematsu; T Masui; H Fukami; M Yamamoto; H Nakanishi; K Inada; M Kusakabe; T Sakakura
Journal:  Int J Cancer       Date:  1996-04-10       Impact factor: 7.396

10.  A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice.

Authors:  M Harvey; H Vogel; D Morris; A Bradley; A Bernstein; L A Donehower
Journal:  Nat Genet       Date:  1995-03       Impact factor: 38.330

View more
  5 in total

Review 1.  Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.

Authors:  Shengliang Zhang; Lindsey Carlsen; Liz Hernandez Borrero; Attila A Seyhan; Xiaobing Tian; Wafik S El-Deiry
Journal:  Biomolecules       Date:  2022-04-06

Review 2.  Animal models of colorectal cancer.

Authors:  Robert L Johnson; James C Fleet
Journal:  Cancer Metastasis Rev       Date:  2013-06       Impact factor: 9.264

3.  The pleiotropic phenotype of Apc mutations in the mouse: allele specificity and effects of the genetic background.

Authors:  Richard B Halberg; Xiaodi Chen; James M Amos-Landgraf; Alanna White; Kristin Rasmussen; Linda Clipson; Cheri Pasch; Ruth Sullivan; Henry C Pitot; William F Dove
Journal:  Genetics       Date:  2008-08-24       Impact factor: 4.562

Review 4.  ANIMAL MODELS FOR COLORECTAL CANCER.

Authors:  Alana Serrano Campelo DE-Souza; Thais Andrade Costa-Casagrande
Journal:  Arq Bras Cir Dig       Date:  2018-07-02

5.  Constitutive activation of mitogen-activated protein kinase kinase (MEK1) in ileal enterocytes leads to dysplasia and a predisposition to cancer.

Authors:  Benjamin L Shneider; Nahir Cortes-Santiago; Deborah A Schady; Swapna Krishnamoorthy; Sundararajah Thevananther; Kimal Rajapakshe; Dimuthu Perera; Shixia Huang; Cristian Coarfa
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2021-01-20       Impact factor: 4.052

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.